Can biatrial dilatation be caused by atrial tachycardia?

Can Atrial Tachycardia Cause Biatrial Dilatation?

Yes, atrial tachycardia can definitively cause biatrial dilatation through the mechanism of tachycardia-induced cardiomyopathy, which affects both atrial and ventricular chambers and is reversible with arrhythmia control.

Mechanism and Pathophysiology

Atrial tachycardia causes biatrial dilatation through a well-established process called tachycardia-induced cardiomyopathy. The 2016 AHA Scientific Statement 1 clearly describes that chronic supraventricular tachycardias, including atrial tachycardia, result in biventricular dilatation along with decreased contractility and elevated filling pressures. While the guidelines focus primarily on ventricular effects, the same pathophysiological mechanisms affect the atria:

• Abnormal myocardial and cellular remodeling occurs with chronic rapid atrial rates
• Neurohormonal activation including renin-angiotensin system activation, increased aldosterone, norepinephrine, and epinephrine
• Proposed mechanisms include myocardial energy depletion, decreased energy utilization, myocardial ischemia, and abnormal calcium handling 1

The 2011 ACC/AHA/ESC guidelines 2 explicitly state that tachycardia-related remodeling can cause atrial dilatation as part of the substrate that develops due to sustained tachycardia.

Clinical Evidence

Multiple case reports document this relationship:

• A 2026 case 3 described a child with restrictive cardiomyopathy who had marked biatrial dilatation with atrial tachycardia as the precipitating arrhythmia
• Historical cases 4, 5, 6 demonstrate dilated cardiomyopathy secondary to chronic ectopic atrial tachycardia that resolved after treatment
• The 2006 ACC/AHA/ESC guidelines 7, 8 note that persistent AF causes mean LA and RA volumes to increase over time, and restoration of sinus rhythm decreases these volumes

Reversibility is Key

The critical diagnostic and therapeutic point is that this process is reversible 1. The 2016 AHA statement emphasizes that "reversibility of the cardiomyopathy with treatment of the arrhythmia is the rule, although this may not be complete in all cases." Treatment focused on aggressive elimination or control of the tachycardia—often requiring catheter ablation—can lead to normalization of chamber dimensions.

Important Clinical Caveats

1. Duration matters: The initial insult can develop over 1 month to years, but recurrence of arrhythmia can cause rapid decline in cardiac function within 6 months 1

2. Incomplete recovery: During the recovery phase, hypertrophy and persistent diastolic dysfunction may occur, suggesting irreversible structural changes despite apparent recovery 1

3. Persistent risk: Sudden death has been described even after elimination of tachycardia and near-normalization of ejection fraction, suggesting persistent ultrastructural changes 1

4. Heart rate threshold: While data suggest heart rates >100 bpm can lead to cardiomyopathy, the exact threshold for tachycardia-induced cardiomyopathy is not defined 1

Management Approach

Maintenance of sinus rhythm or control of ventricular rate is indicated in treating patients with tachycardia-induced cardiomyopathy (Class I recommendation) 1. The treatment algorithm should be:

1. Identify and confirm atrial tachycardia as the causative mechanism (tachyarrhythmia preceding chamber dilatation)
2. Pursue aggressive rhythm control - catheter ablation is often curative and should be strongly considered 1
3. Initiate standard heart failure therapy to attenuate adverse remodeling during recovery
4. Monitor for recovery - expect improvement but recognize that complete normalization may not occur
5. Maintain vigilance for recurrence, as repeat tachycardia episodes cause rapid deterioration

The 2025 consensus 9 further supports early catheter ablation for any symptomatic, recurrent atrial tachycardia, which aligns with preventing or reversing tachycardia-induced structural changes including biatrial dilatation.